CLINICAL_TRIALS
trial_result
· 2018-02-27
Clinical Trial Update: The Study of the Efficacy and the Safety of Flumatinib vs Imatinib as First Line Treatment in Patients With CML [Phase 3]
Summary
A Phase 3 trial comparing flumatinib to imatinib as first-line therapy for chronic myeloid leukemia has completed.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd. | Conditions: CML, CML-CP,MMR,TKI | Phase 3 | Status: COMPLETED